Literature DB >> 3257508

The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein.

R Schwartz-Albiez1, B Dörken, W Hofmann, G Moldenhauer.   

Abstract

The human B lymphocyte-associated CD37 antigen (gp40-52) has been characterized by the monoclonal antibody HD28. The CD37 antigen is strongly expressed on surface immunoglobulin positive B lymphocytes and weakly on a subpopulation of T lymphocytes and myeloid cells. The total molecular mass of the antigen ranges from approximately 40 to 52 kDa in B cell-derived leukemias and malignant lymphomas as well as in normal and anti-mu/B cell growth factor-activated tonsillar B cells. The polydisperse nature of the electrophoretic pattern of the CD37 antigen was found to be due to a microheterogeneity in its carbohydrate moiety. Biochemical analysis showed that the CD37 antigen derived from B cell-lines BJAB and LICR-LON-HMy2 consists of a single chain protein core of approximately 25 kDa to which two N-linked, complex carbohydrate antennae of various length are bound. The glycosylation of the molecule comprises about 50% of the total molecular mass. The molecule does not contain O-linked carbohydrate chains. In contrast, the non-Hodgkin's lymphoma cell line, OCI.LY1, which is growth-dependent on human serum, carries a CD37 antigen with an additional carbohydrate chain resulting in a total molecular mass of approximately 40 to 64 kDa. At the electron microscopy level, this cell surface-expressed antigen was found to be associated with intracellular vesicles. The subcellular distribution of the CD37 antigen may reflect a function of this antigen both at the cell surface and in the cytoplasm. We found that, both due to its peculiar biochemical structure and its ultrastructural distribution, the CD37 antigen closely resembles the 46-kDa species of the mannose 6-phosphate receptor. The implications of this possible congruence for the function of the CD37 antigen are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257508

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Specific interactions among transmembrane 4 superfamily (TM4SF) proteins and phosphoinositide 4-kinase.

Authors:  R L Yauch; M E Hemler
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

2.  AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Authors:  Daniel S Pereira; Claudia I Guevara; Liqing Jin; Nathan Mbong; Alla Verlinsky; Ssucheng J Hsu; Hector Aviña; Sher Karki; Joseph D Abad; Peng Yang; Sung-Ju Moon; Faisal Malik; Michael Y Choi; Zili An; Kendall Morrison; Pia M Challita-Eid; Fernando Doñate; Ingrid B J Joseph; Thomas J Kipps; John E Dick; David R Stover
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

3.  Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins).

Authors:  F Berditchevski; M M Zutter; M E Hemler
Journal:  Mol Biol Cell       Date:  1996-02       Impact factor: 4.138

Review 4.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Authors:  Rosa Lapalombella; Yuh-Ying Yeh; Liwen Wang; Asha Ramanunni; Sarwish Rafiq; Shruti Jha; Justin Staubli; David M Lucas; Rajeswaran Mani; Sarah E M Herman; Amy J Johnson; Arletta Lozanski; Leslie Andritsos; Jeffrey Jones; Joseph M Flynn; Brian Lannutti; Peter Thompson; Paul Algate; Scott Stromatt; David Jarjoura; Xiaokui Mo; Dasheng Wang; Ching-Shih Chen; Gerard Lozanski; Nyla A Heerema; Susheela Tridandapani; Michael A Freitas; Natarajan Muthusamy; John C Byrd
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

6.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

7.  The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes.

Authors:  K I Virtaneva; P Angelisová; T Baumruker; V Horejsí; H Nevanlinna; J Schröder
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 8.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

9.  Chromosomal localization of three human genes coding for A15, L6, and S5.7 (TAPA1): all members of the transmembrane 4 superfamily of proteins.

Authors:  K I Virtaneva; N Emi; J S Marken; A Aruffo; C Jones; N K Spurr; J P Schröder
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

10.  Hepatic gene expression profiling reveals protective responses in Atlantic salmon vaccinated against furunculosis.

Authors:  Stanko Skugor; Sven Martin Jørgensen; Bjarne Gjerde; Aleksei Krasnov
Journal:  BMC Genomics       Date:  2009-10-30       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.